PEGYLATED INTERFERON LAMBDA (PEG-IFN-lambda) PHASE 2 DOSE-RANGING, ACTIVE-CONTROLLED STUDY IN COMBINATION WITH RIBAVIRIN (RBV) FOR TREATMENT-NAiVE HCV PATIENTS (GENOTYPES 1, 2, 3 OR 4): SAFETY, VIRAL RESPONSE, AND IMPACT OF IL-28B HOST GENOTYPE THROUGH WEEK 12

Published

Conference Paper

Full Text

Duke Authors

Cited Authors

  • Muir, AJ; Lawitz, E; Ghalib, RH; Sussman, NL; Anderson, F; Everson, GT; Jacobson, IM; Lopez-Talavera, JC; Hillson, JL; Gray, TE; Fontana, D; Ramos, EL; Rodriguez-Torres, M

Published Date

  • October 1, 2010

Published In

Volume / Issue

  • 52 / 4

Start / End Page

  • 715A - 716A

Published By

Pages

  • 2

International Standard Serial Number (ISSN)

  • 0270-9139

Conference Name

  • 61st Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases

Conference Location

  • Boston, MA

Conference Start Date

  • October 29, 2010

Conference End Date

  • November 2, 2010